Disparities in Access to GLP-1 Weight-Loss Medications Highlight Health Inequities
For many individuals living with obesity, medications like Wegovy and Mounjaro present a promising avenue for substantial weight loss without the need for surgical intervention. However, a troubling trend has emerged from data provided by a private healthcare provider in England, indicating that prescription rates for these medications are lowest in communities where obesity is most prevalent. Wegovy, which contains semaglutide, works by targeting the GLP-1 hormone pathway involved in appetite regulation, while Mounjaro contains tirzepatide, which affects both GLP-1 and another hormone pathway known as GIP. Clinical trials have shown that participants taking semaglutide lost an average of 14.9% of their initial weight after 68 weeks, whereas those on the highest dose of tirzepatide lost an average of 20.9% after 72 weeks. Both trials included dietary and physical activity support to enhance outcomes.
A comprehensive analysis conducted in 2026 involving 113,630 patients revealed that private prescribing rates for these medications were 32% lower in the most deprived areas of England compared to the least deprived. When adjusted for the higher prevalence of obesity in these deprived areas, the estimated prescribing rate per person living with obesity was found to be 120% higher in the least deprived regions. Although this analysis does not definitively establish that cost is the sole factor behind this disparity, it does suggest that affordability may play a significant role in access to treatment.
As the NHS continues to roll out access to these medications, the question arises: does the ability to pay influence who can access treatment sooner? Obesity is often framed as a consequence of personal choices; however, research indicates that factors such as genetics, biological processes, income, education, food prices, and living environments significantly impact body weight. A review of socioeconomic evidence highlights that in high-income countries, lower socioeconomic status correlates with a higher likelihood of obesity, particularly among women.
Cost is a critical factor affecting dietary choices, as a meta-analysis across ten countries found that healthier dietary patterns typically incur higher costs than less healthy options, although this varies based on specific foods and preparation methods. Despite this knowledge, England's obesity policy has frequently focused on encouraging individual behavior change rather than addressing the systemic issues that contribute to obesity.
An analysis of 14 government strategies from 1992 to 2020 found that many proposed policies placed excessive demands on individual agency, often failing to effectively reduce health inequalities. While medications can enhance treatment for individuals, they do not address the underlying conditions that increase the likelihood of obesity.
The National Institute for Health and Care Excellence (NICE) in England recommends tirzepatide for adults with a body mass index (BMI) of at least 35 and at least one weight-related health condition. Lower BMI thresholds apply to certain ethnic groups due to their increased risk of weight-related illnesses at lower BMI levels. NHS England estimates that approximately 3.4 million adults meet the NICE criteria for these medications. Tirzepatide is accessible to eligible patients through specialist weight-management services, contingent on a clinician's decision. However, access through primary care is more limited and is being implemented based on BMI and the number of related health conditions.
The phased rollout in primary care is expected to cover around 220,000 individuals during its initial three years, with approved funding allowing up to 12 years to make treatment available to the entire eligible population. Consequently, many individuals who meet the broader NICE criteria may experience delays of several years before gaining access to primary care.
Private prescriptions offer an alternative route for those who meet the clinical requirements and can afford the treatment, but the analysis suggests that affordability may influence access to these medications. As NHS prescribing continues to be phased in, individuals who can afford private treatment may be able to access these medications sooner than those who cannot, potentially exacerbating the financial divide for those in more deprived areas.
If prolonged treatment is necessary, the financial burden could increase significantly. A systematic review published in 2026 indicated that participants typically regained around 60% of the weight lost within a year of discontinuing GLP-1 receptor agonists. While long-term evidence remains limited, it is clear that some patients may require ongoing treatment or alternative maintenance plans to sustain their weight loss.
For those paying privately, maintaining treatment over an extended period could entail substantial ongoing costs. Furthermore, the effectiveness of these medications may depend on the support available alongside the prescriptions. These medications work by reducing appetite and food intake, which can complicate efforts to obtain adequate nutrition from a smaller volume of food. Clinical guidelines recommend assessing diet quality and the risk of nutrient deficiencies and muscle loss, while also providing individualized advice during treatment. A recent article in Nature Medicine cautioned that unequal access to nutritious food and professional support could lead to unequal treatment outcomes.
NHS England mandates that nutritional and behavioral support accompany tirzepatide prescriptions. Ensuring that this support is accessible in practice is particularly crucial for patients already facing food insecurity or challenges in accessing healthcare.
GLP-1-based medications have the potential to enhance health for many individuals living with obesity. However, their broader impact on health inequalities will rely on the speed of NHS access expansion and whether treatment reaches communities with the highest clinical needs. The provision of appropriate ongoing support will also be vital in determining how safely and effectively individuals can utilize these medications. Without an equitable system in place, it is possible for population health to improve while the gap between socioeconomic groups widens.




